#1 out of 219.96%
health3h ago
Blood test added to colorectal cancer screening options by cancer group
Nbcnews.com and 1 more
- The American Cancer Society added Guardant Health's Shield blood test to its recommended colorectal cancer screening options.
- The Shield test is not meant to replace colonoscopies, but to reach people who may otherwise skip screening.
- FDA approved Shield in 2024 and it detects DNA fragments released by cancerous tumors.
- The guidance notes Shield is best for those who can’t or won’t undergo colonoscopy or stool tests.
- The test costs about $895 out of pocket and insurance coverage is not yet clear.
- Experts say colonoscopy remains the most effective screening tool, with other tests offering additional options.
- Cologuard and ColoSense are stool-based tests suggested as alternatives or complements to colonoscopy.
- The American Cancer Society emphasizes screening uptake and early detection across age groups.
- The guidance notes there is no data yet showing whether the Shield test saves lives in the long run.
- Colorectal cancer remains a leading cause of death among younger adults, underscoring the value of varied screening options.
Vote 1
